[Comparative effectiveness of carbapenems and alternative antibiotics for the treatment of bacteraemia and/or urinary tract infectious disease by Enterobacteriaceae producing extended-spectrum β-lactamase]
Dong Ah Park, Jinnie Rhee, Na Rae Lee, Ji Jeong Park, Soo Kyung Son, Kyong Ran Peck, Su Yeun Moon, Eun-Jeong Joo, Jae-Ki Choi, Jae-Hoon Ko
Record ID 32016001008
Korean
Original Title:
ESBL 생성 장내세균에 의한 균혈증 및 요로감염에서 카바페넴과 다른 항생제 대안 치료법간 임상효과 비교연구
Authors' recommendations:
This study systematically reviewed the recently published evidence to evaluate the clinical effectiveness of carbapenems and other alternative antibiotics in treating bacteremia and urinary tract infection caused by ESBL-producing Enterobacteriaceae and analyzed the comparative clinical outcomes of those therapies using multi-center data in Korea.
Although there was no clear evidence that superiority of carbapenem in empirical therapy, this study results suggest that carbapenem therapy is associated with a reduction of overall mortality when it is used as a definitive treatment in bacteremia caused by ESBL-producing Enterobacteriaceae, However, considering an increasing carbapenem resistance and non-inferiority of BL/BLIs use over carbapenems according to the study results, BL/BLIs can be used as alternatives for the treatment of patients with ESBL-positive Enterobacteriaceae bacteraemia.
In patients with ESBL-positive Enterobacteriaceae urinary tract infection, the role of carbapenem and other antibiotics should be further evaluated for empirical and definitive treatment.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=228
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
South Korea
MeSH Terms
- Anti-Bacterial Agents
- Bacteremia
- Carbapenems
- Enterobacteriaceae
- Humans
- Urinary Tract Infections
- beta-Lactamases
Contact
Organisation Name:
National Evidence-based healthcare Collaborating Agency
Contact Address:
National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name:
int@neca.re.kr
Contact Email:
int@neca.re.kr
Copyright:
National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.